益生股份(002458.SZ):2024年員工持股計劃完成股票購買
格隆匯7月17日丨益生股份(002458.SZ)公佈,截至本公吿披露日,公司2024年員工持股計劃已完成股票購買,購買時間為2024年07月17日,購買方式為二級市場競價交易方式,購買數量為1,057,900股,佔公司總股本的0.096%,成交均價為8.518元/股,成交總金額為9,011,733.23元(含交易費用)。本次員工持股計劃實際認購份額未超過股東大會審議通過的擬認購份額上限。認購股票所需資金來源為本次員工持股計劃持有人獲受的激勵基金。本次持股計劃購買的股票將按照規定予以鎖定,鎖定期自公司本次員工持股計劃購買完成之日起12個月,即2024年07月17日至2025年07月16日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.